Rosiglitazone treatment alleviates inflammation and improves liver function in overweight women with polycystic ovary syndrome: a randomized placebo-controlled study

被引：48

作者：

Rautio, Katrina

Tapanainen, Juha S.

Ruokonen, Aimo

Morin-Papunen, Laure C.

机构：

[1] Oulu Univ Hosp, Dept Obstet & Gynecol, FIN-90014 Oulu, Finland

[2] Oulu Univ Hosp, Dept Clin Chem, FIN-90014 Oulu, Finland

来源：

FERTILITY AND STERILITY | 2007年 / 87卷 / 01期

基金：

芬兰科学院;

关键词：

D O I：

10.1016/j.fertnstert.2006.05.061

中图分类号：

R71 [妇产科学];

学科分类号：

100211 [妇产科学];

摘要：

In a randomized, placebo-controlled study, we studied the effects of 4 months' treatment with rosiglitazone on low-grade inflammation, liver function, lipid levels, and blood pressure in 30 overweight women with polycystic ovary syndrome. Rosiglitazone significantly decreased serum C-reactive protein levels, white blood cell count, and alanine aminotransferase enzyme activity but did not affect lipid or blood pressure levels. Placebo had no effect on any parameters.

引用

收藏

页码：202 / 206

页数：5

相关论文

共 44 条

[1]

Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity [J].

Baillargeon, JP ;

Jakubowicz, DJ ;

Iuorno, MJ ;

Jakubowicz, S ;

Nestler, JE .

FERTILITY AND STERILITY, 2004, 82 (04) :893-902

[2]

Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome [J].

Belli, SH ;

Graffigna, MN ;

Oneto, A ;

Otero, P ;

Schurman, L ;

Levalle, OA .

FERTILITY AND STERILITY, 2004, 81 (03) :624-629

[3]

Inflammatory bio-markers and cardiovascular risk prediction [J].

Blake, GJ ;

Ridker, PM .

JOURNAL OF INTERNAL MEDICINE, 2002, 252 (04) :283-294

[4]

Increased C-reactive protein levels in the polycystic ovary syndrome: A marker of cardiovascular disease [J].

Boulman, N ;

Levy, Y ;

Leiba, R ;

Shachar, S ;

Linn, R ;

Zinder, O ;

Blumenfeld, Z .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05) :2160-2165

[5]

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome [J].

Chang, J ;

Azziz, R ;

Legro, R ;

Dewailly, D ;

Franks, S ;

Tarlatzis, BC ;

Fauser, B ;

Balen, A ;

Bouchard, P ;

Dahlgren, E ;

Devoto, L ;

Diamanti, E ;

Dunaif, A ;

Filicori, M ;

Homburg, R ;

Ibanez, L ;

Laven, J ;

Magoffin, D ;

Nestler, J ;

Norman, RJ ;

Pasquali, R ;

Pugeat, M ;

Strauss, J ;

Tan, S ;

Taylor, A ;

Wild, R ;

Wild, S ;

Ehrmann, D ;

Lobo, R .

FERTILITY AND STERILITY, 2004, 81 (01) :19-25

[6]

A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors [J].

Chiquette, E ;

Ramirez, G ;

DeFronzo, R .

ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (19) :2097-2104

[7]

Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients [J].

Daniel, S ;

Ben-Menachem, T ;

Vasudevan, G ;

Ma, CK ;

Blumenkehl, M .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 1999, 94 (10) :3010-3014

[8]

Day C P, 2002, J Gastroenterol Hepatol, V17 Suppl 3, pS377, DOI 10.1046/j.1440-1746.17.s3.31.x

[9]

Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis [J].

Dunaif, A .

ENDOCRINE REVIEWS, 1997, 18 (06) :774-800

[10]

Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome [J].

Ehrmann, DA ;

Schneider, DJ ;

Sobel, BE ;

Cavaghan, MK ;

Imperial, J ;

Rosenfield, RL ;

Polonsky, KS .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (07) :2108-2116

← 1 2 3 4 5 →